Exchange: NASDAQ·Updated 07:44 PM EST

RLAY News

News
all
press releases
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CEO Sells $777,498.26 in Stock
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CEO Sanjiv Patel sold 48,202 shares of the business's stock in a transaction that occurred on Thursday, November 19th. The stock was sold at an average price of $16.13, for a total value of $777,498.26. Following the completion of the...
MarketBeat
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CEO Sells $777,498.26 in Stock
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CEO Sanjiv Patel sold 48,202 shares of the business's stock in a transaction that occurred on Thursday, November 19th. The stock was sold at an average price of $16.13, for a total value of $777,498.26. Following the completion of the...
MarketBeat
More News
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 32,717 shares of the stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $16.51, for a total transaction of $540,157.67. Following the completion of the sale, the chief...
MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Donald Bergstrom sold 10,269 shares of the company's stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $16.51, for a total transaction of $169,541.19. Following the...
MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold r...
MarketBeat
RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.
Zacks
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
Zacks
Key PointsThe sale had an approximate value of nearly $350,000...
Nasdaq News: Markets
AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.
Zacks
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Zacks
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.